SLC16A7 and prostate carcinoma: The strong and cytoplasmic expression of MCT2 in prostate cancer cells not only sheds some light on the involvement of MCT2 in tumours that might not rely mainly on glycolytic metabolism, but also contributes to the understanding of particularities in the metabolism of prostate cancer cells that make it metabolically unique in comparison to other malignancies.